Anatomy hub
Hip: Options and What the Evidence Actually Shows
Hip osteoarthritis and avascular necrosis (AVN) are distinct problems. OA is common; early AVN is a cleaner mechanistic case for regenerative discussion.
Anatomy and clinical context
The hip is a deep ball-and-socket joint. Cartilage loss produces mechanical pain and limited motion; AVN is bone death in the femoral head that can collapse the joint if untreated.
Conservative care and injections help many OA patients delay arthroplasty. AVN pathways depend heavily on stage — early disease is where non-arthroplasty options are most often explored.
Illustration of the hip joint
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Activity modification, PT, weight management, and oral meds for symptomatic OA.
- Step 2
Injections
Image-guided corticosteroid or orthobiologic injectates; core decompression ± adjuncts in selected early AVN.
- Step 3
Surgery
Total hip arthroplasty for end-stage OA or collapsed AVN; other reconstructive options as indicated.
Where cell therapy fits
Hip OA regenerative data is thinner than knee. Early AVN attracts mechanistic interest because preserving the femoral head is the goal — still a physician-led decision with evolving evidence.
- Hip OA injectates face the same dose and potency constraints as other joints.
- Early AVN is often cited as a cleaner biological story than late OA — volume is lower; specialty interest is higher.
- Banking younger cells supports future protocols that may need expanded autologous product rather than a single same-day draw.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Stempeucel
Approved product (India) · Regulatory approval (2020)
Culture-expanded MSC product approved in India — example of dose-enabled products showing clinical pathway beyond same-day unexpanded injectates.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.